Daily Newsletter

08 December 2023

Daily Newsletter

08 December 2023

Sanofi makes $140m deal for AI drug discovery

The collaboration between Sanofi and Aqemia is not just a financial transaction; it signifies a broader shift in the industry towards embracing AI.

GlobalData December 07 2023

In a new development in the pharmaceutical sector, Sanofi, a prominent global pharmaceutical company, has entered a $140m deal with Aqemia, a French pharmaceutical technology company. This partnership seeks to utilize advanced physics algorithms and generative artificial intelligence (AI) in drug discovery innovation.

Aqemia, built on years of intensive research into physics algorithms, has developed a streamlined technology that integrates physics-based algorithms and generative AI to expedite drug discovery processes. Collaborating with Sanofi, Aqemia will apply its innovative approach to identify and create small molecules with potential across various therapeutic areas.

The significance of this collaboration lies in the promise of accelerated drug development. Sanofi's commitment to pay up to $140m in upfront and milestone payments underscores the potential perceived in Aqemia's advanced technology. This financial deal provides Aqemia with the resources needed to further refine its methods and drive progress in drug discovery.


Aqemia's streamlined technology is poised to contribute to the development of superior pharmaceuticals at an unprecedented pace. By combining physics algorithms and generative AI, Aqemia can navigate the complexities of drug discovery more efficiently, offering an innovative approach to finding small molecules for therapeutic applications.

This partnership is part of a broader trend within the pharmaceutical community, where industry leaders are increasingly turning to AI to enhance and expedite drug development processes. The integration of advanced technologies like physics algorithms and generative AI represents a collective effort to harness the power of artificial intelligence in creating safer, more effective medications.

The $140m deal between Sanofi and Aqemia marks a significant milestone in the pharmaceutical industry's embrace of AI-driven solutions. This collaboration not only underscores the potential of Aqemia's technology but also reinforces the industry's commitment to leveraging innovative approaches to address the growing demand for novel and effective pharmaceuticals.

Why are healthcare companies hesitant to invest in the metaverse?

Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns.

Healthcare industry continues to be highly vulnerable to cyberattacks

Cybersecurity is a growing market in the medical devices sector for several reasons. Medical devices often collect and contain vulnerable data, such as patient medical information. Legacy medical devices are a cause for concern because they likely were not designed with cyberattacks in mind. With the adoption of EHR systems, telemedicine measures, mobile health apps, and other connected devices, there is increased vulnerability to cyberattacks.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close